patients suffering from rare conditions should be entitled to the same quality of treatment as other patients; it is therefore necessary to stimulate the research, development and bringing to the market of appropriate medications by the pharmaceutical industry; incentives for the development of orphan medicinal products have been available in the United States of America since 1983 and in Japan since 1993;
Recital 2, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…
Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision
Fourthly, it is apparent from recitals 1, 2 and 4 in the preamble to Regulation No 141/2000 that the intention of the legislature was to provide for measures to stimulate the research and development of potential orphan medicinal products …
9 Sep 2010 · 62007TJ0264
Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision
It is apparent from recitals 1 and 2 of Regulation No 141/2000 that the European Union is seeking to stimulate the research, development and bringing to the market of appropriate medications by the pharmaceutical industry for conditions …
24 Sep 2025 · 62022TJ0483
Opinion of Advocate General Hogan delivered on 11 September 2019. PTC Therapeutics International Ltd v European Medicines Agency.Decision
The concept of orphan medicinal products is perhaps best explained by the first and second recitals to Regulation No 141/2000: ’Whereas: some conditions occur so infrequently that the cost of developing and bringing to the market a …
11 Sep 2019 · 62018CC0175
Opinion of Advocate General Emiliou delivered on 11 July 2024. Mylan IRE Healthcare Ltd v European Commission.Decision
The appellant raises two arguments that consist in claiming that the judgment under appeal hinders the attainment of the objective pursued by Regulation No 141/2000, namely ensuring that patients suffering from rare diseases and whose …
11 Jul 2024 · 62022CC0237